Home > Products > Novel inhibitors

Sovleplenib

  Cat. No.:  DC48364   Featured
Chemical Structure
1415792-84-5
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
Get Quotation Now
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
Sovleplenib is a highly potent inhibitor of spleen tyrosine kinase (Syk), derived from the innovative research disclosed in patent WO2012167733 A1. This compound demonstrates significant potential in modulating Syk-mediated signaling pathways, offering a promising therapeutic approach for conditions where Syk activity plays a critical role. Its development underscores the ongoing advancements in targeted kinase inhibition, providing a valuable tool for both research and potential clinical applications in immune-related and inflammatory diseases.
Chemicals PropertiesBiological activity COA & MSDSRelated productsDatasheet
Cas No.: 1415792-84-5
Chemical Name: Sovleplenib
Synonyms: Sovleplenib;9CL6353KHO;Pyrido[3,4-b]pyrazin-5-amine, 7-[4-[1-(methylsulfonyl)-4-piperidinyl]phenyl]-N-[(2S)-2-morpholinylmethyl]-;Sovleplenib [INN];GTPL11886;compound 225 [WO2012167733A1];(S)-7-(4-(1-(Methylsulfonyl)piperidin-4-yl)phenyl)-N-(morpholin-2-ylmethyl)pyrido(4,3-b)pyrazin-5-amine;1415792-84-5;(S)-7-(4-(1-(METHYLSULFONYL)PIPERIDIN-4-YL)PHENYL)-N-(MORPHOLIN-2-YLMETHYL)PYRIDO[3,4-B]PYRAZIN-5-AMINE;Sovleplenib [WHO-DD];HY-145598;MS-28979;Sovleplenib (USAN/INN);CS-0376654;SCHEMBL14242080;Spleen Tyrosine Kinase Inhibitor HMPL-523;EX-A7664;Syk Inhibitor HMPL-523;DA-67702;AKOS040752025;7-[4-(1-methylsulfonylpiperidin-4-yl)phenyl]-N-[[(2S)-morpholin-2-yl]methyl]pyrido[3,4-b]pyrazin-5-amine;F78019;D12953;HMPL-523;compound 225 (WO2012167733A1);UNII-9CL6353KHO;HMPL-523 [WHO-DD];GLXC-27900;HMPL523
SMILES: S(C)(N1CCC(C2C=CC(C3C=C4C(=C(N=3)NC[C@@H]3CNCCO3)N=CC=N4)=CC=2)CC1)(=O)=O
Formula: C24H30N6O3S
M.Wt: 482.598403453827
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
MSDS
TITLE DOWNLOAD
MSDS_32255_DC48364_1415792-84-5
COA
LOT NO. DOWNLOAD
Cat. No. Product name Field of application
DC48364 Sovleplenib Sovleplenib is a highly potent inhibitor of spleen tyrosine kinase (Syk), derived from the innovative research disclosed in patent WO2012167733 A1. This compound demonstrates significant potential in modulating Syk-mediated signaling pathways, offering a promising therapeutic approach for conditions where Syk activity plays a critical role. Its development underscores the ongoing advancements in targeted kinase inhibition, providing a valuable tool for both research and potential clinical applications in immune-related and inflammatory diseases.
DC48025 Cevidoplenib dimesylate Cevidoplenib is an orally available inhibitor of spleen tyrosine kinase (Syk), with potential anti-inflammatory and immunomodulating activities.
DC40848 SRX3207 SRX3207 is an orally active and first-in-class dual Syk/PI3K inhibitor. SRX3207 possesses anti-tumor activity.
DC28254 Lanraplenib monosuccinate Lanraplenib monosuccinate (GS-9876 monosuccinate) is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. Lanraplenib monosuccinate (GS-9876 monosuccinate) inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans.
X
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Site Map|Privacy PolicyCopyright © 2018-2020 All Rights Reserved. Technical Support:KuuJia